Posoleucel (ALVR105)
Sponsors
AlloVir
Conditions
Adenovirus InfectionBK Virus InfectionCytomegalovirus InfectionsEpstein-Barr Virus InfectionsHemorrhagic CystitisHuman Herpes Virus-6 InfectionJC Virus Infection
Phase 2
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
CompletedNCT04693637
Start: 2021-01-15End: 2023-01-19Updated: 2024-05-09
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
TerminatedNCT05305040
Start: 2022-03-24End: 2024-01-30Updated: 2024-05-16